Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 50OTHER 30NIH 24OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

apatinib 2Immunotherapy 2Drug Therapy 2130-nm albumin-bound paclitaxel 2toripalimab 1spartalizumab 1darolutamide 1camrelizumab 1Surgical Procedures, Operative 1Standard of Care 1Radiation 1Platinum Compounds 1Mitomycin 1Low-Level Light Therapy 1Lisaftoclax 1Indocyanine Green 1Gemcitabine 1Everolimus 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Bevacizumab × 30 days × Clear all
NCT07472153 2026-05-28

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡